This technology features a method for preventing or treating radiation-associated loss of bone mass, bone density, or bone strength in a subject. This technology involves administering to the subject an amount of anti-resorptive or osteoclast-inhibiting compound sufficient to prevent or mitigate loss of bone mass, density, or strength caused by radiation-associated increases in the number or activity of osteoclasts.
Existing antiresorptive therapies (bisphosphonates: alendronate/Fosamax, risedronate/Actonel, ibandronate/Boniva, zoledronate/Zometa/Reclast, and pamidronate/Aredia; and anti-RANKL: denosumab/Prolia/Xgeva) for osteoporosis are effective through the inhibition of osteoclastic bone resorption. Data indicate that exposure to ionizing radiation causes a very rapid and profound activation of osteoclasts, to the degree that treatment will likely become necessary once the problem (rapid bone loss) is fully identified.
This work was done by Jeffrey S. Willey and Ted A. Bateman of Clemson University Dept. of Bioengineering for Johnson Space Center. For further information, contact the JSC Technology Transfer Office at (281) 483-3809. MSC-25124-1